Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMPR1B | O00238 | 2/20 | 0.44 |
| ▸ | BMPR1A | P36894 | 2/20 | 0.44 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.44 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.34 |
| ▸ | BRD4 | O60885 | 3/20 | 0.33 |
| ▸ | INSR | P06213 | 2/20 | 0.32 |
| ▸ | MET | P08581 | 2/20 | 0.32 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | BRD2 | P25440 | 1/20 | 0.31 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20095715 | 0.86 | BMPR1B (0.41) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL10177054 | 0.72 | ALDH1A1 (0.51) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL20095590 | 0.72 | RIPK1 (0.43) | BMPR1BBMPR1AACVRL1ACVR1RIPK1 | |
| SCHEMBL11713004 | 0.71 | MEN1 (0.49) | BRD4CREBBP | |
| SCHEMBL30832131 | 0.71 | BMPR1B (0.49) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL21220686 | 0.71 | BMPR1B (0.38) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL19224681 | 0.71 | BMPR1B (0.49) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL8553135 | 0.71 | BMPR1B (0.46) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL520474 | 0.71 | ATAD2 (0.53) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL19980481 | 0.71 | MAOA (0.49) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12139482-B2 | Bicyclic pyridone lactams and methods of use thereof | GENENTECH, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| EP-3526219-B1 | BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2021-12-15 | — | — | EP | disclosed |
| EP-3526219-B1 | BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2021-12-15 | — | — | EP | disclosed |
| US-20210163475-A1 | BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210163475-A1 | BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-06-03 | — | — | US | disclosed |
| US-10947226-B2 | Bicyclic pyridone lactams and methods of use thereof | GENENTECH, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-10947226-B2 | Bicyclic pyridone lactams and methods of use thereof | GENENTECH, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20190241565-A1 | BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-08 | — | — | US | disclosed |
| US-20190241565-A1 | BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163475-A1 | BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF | CYP3A5, C5, PDXK | BMPR1B 313/4885BMPR1A 266/4885ACVRL1 1410/4885 |
| US-10947226-B2 | Bicyclic pyridone lactams and methods of use thereof | CYP3A5, C5, PDXK | BMPR1B 313/4885BMPR1A 266/4885ACVRL1 1410/4885 |
| US-20190241565-A1 | BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF | CYP3A5, C5, PDXK | BMPR1B 313/4885BMPR1A 266/4885ACVRL1 1410/4885 |
| US-12139482-B2 | Bicyclic pyridone lactams and methods of use thereof | CYP3A5, C5, PDXK | BMPR1B 313/4885BMPR1A 266/4885ACVRL1 1410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.